Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Moleculin Biotech (MBRX) Shares Outstanding (Weighted Average) (2016 - 2025)

Moleculin Biotech's Shares Outstanding (Weighted Average) history spans 10 years, with the latest figure at $7.6 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Weighted Average) at $7.6 million for Q4 2025, up 5420.09% from a year ago — trailing twelve months through Dec 2025 was $7.6 million (up 5420.09% YoY), and the annual figure for FY2025 was $7.6 million, up 5420.09%.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $7.6 million at Moleculin Biotech, down from $20.8 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $67.8 million in Q2 2025 to a low of $2025.0 in Q1 2025.
  • The 5-year median for Shares Outstanding (Weighted Average) is $2.3 million (2022), against an average of $8.5 million.
  • Peak annual rise in Shares Outstanding (Weighted Average) hit 107285.4% in 2025, while the deepest fall reached 99.81% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $26.9 million in 2021, then plummeted by 99.18% to $220192.0 in 2022, then skyrocketed by 797.22% to $2.0 million in 2023, then crashed by 93.03% to $137720.0 in 2024, then soared by 5420.09% to $7.6 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $7.6 million, $20.8 million, and $67.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.